-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Compound Electrolyte Injection Has Passed the Consistency Evaluation
Category:
发布时间：2024-05-14
【概要描述】
Recently, Shijiazhuang Sihua Pharmaceutical Group’s Compound Electrolyte Injection (500 ml) passed the National Medical Products Administration’s evaluation of generic drug quality and therapeutic equivalence, making the company the second domestic manufacturer to receive approval for this product.
Recently, Shijiazhuang Sihua Pharmaceutical Group’s Compound Electrolyte Injection (500 ml) passed the National Medical Products Administration’s evaluation of generic drug quality and therapeutic equivalence, making it the second domestic manufacturer to receive approval following this review for this product.
According to available information, compound electrolyte injection is primarily used as a source of water and electrolytes and as an alkalinizing agent. This formulation is compatible with blood and blood components and can be administered using the same infusion set either before or after blood transfusion—either as a priming solution, by addition to the blood being infused, or as a diluent for blood cells.
To date, the Group has had 110 product specifications across 81 varieties either approved or deemed to have passed the consistency evaluation.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091